Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript

Mariann Ohanesian
Senior Director of Investor Relations

Thank you, Julian. Good afternoon, and welcome to Puma’s conference call to discuss our earnings results for the third quarter of 2025.

Joining me on the call today are Alan Auerbach, Chief Executive Officer, President, and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial Officer; Heather Blaber, Senior Vice President of Marketing; and Roger Storms, Senior Vice President of Sales.

After the close today, Puma issued a news release detailing earnings results for the third quarter of 2025. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days.

Today’s conference call will include statements about Puma’s future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from those expressed in these forward-looking statements.

For a full discussion of these risks and uncertainties, please review our periodic and current reports filed with the SEC.
https://seekingalpha.com/article/4840492-puma-biotechnology-inc-pbyi-q3-2025-earnings-call-transcript?source=feed_all_articles

Price Over Earnings Overview: Amgen

In the current market session, Amgen Inc. (NASDAQ: AMGN) shares are priced at $295.58, reflecting a slight drop of 0.08%. Over the past month, the stock has increased by 3.56%, yet over the past year, it has declined by 6.68%.

With such mixed performance—stronger in the short term but weaker in the long term—long-term shareholders might want to examine the company’s price-to-earnings (P/E) ratio more closely.

### Comparing Amgen’s P/E Ratio Against Its Peers

The P/E ratio compares the current share price to the company’s earnings per share (EPS). It is commonly used by long-term investors to assess a company’s valuation by analyzing its current price in relation to past earnings, historical data, and the broader market or industry benchmarks, such as the S&P 500.

A higher P/E ratio generally indicates that investors expect better future performance from the company. It may suggest that the stock is overvalued—but not necessarily. Alternatively, it might mean that investors are willing to pay a premium today because they anticipate stronger earnings growth in the coming quarters. This optimism can also be tied to expectations of rising dividends.

In the Biotechnology industry, the average P/E ratio stands at 30.06. In comparison, Amgen’s P/E ratio is lower at 24.19. This discrepancy might lead shareholders to worry that Amgen will perform worse than its industry peers. On the other hand, the stock could be undervalued relative to its competitors, potentially presenting a buying opportunity.

### Final Thoughts

While the price-to-earnings ratio is a valuable metric for evaluating a company’s market performance, it should be used cautiously. A low P/E ratio might indicate undervaluation, but it can also signal weak growth prospects or financial instability.

Moreover, the P/E ratio is just one of many tools that investors should consider when making decisions. It’s important to evaluate it alongside other financial metrics, industry trends, and qualitative factors such as management quality and market position.

By taking a comprehensive approach to analyzing a company’s financial health, investors can make more informed decisions that improve their chances of successful outcomes.
https://www.benzinga.com/insights/news/25/10/48279423/price-over-earnings-overview-amgen

IISER Kolkata Develops ‘Friendly Bacteria’ To Combat Cancer From Within Patient’s Body

Kolkata: A team from the Indian Institute of Science Education and Research (IISER) Kolkata has developed a “friendly bacteria” that can safely and effectively fight cancer from within the patient’s body, the premier institute announced in a statement.

Alongside this breakthrough, the team is also developing a detection system capable of monitoring the progress of the therapy. Together, these innovations mark a new frontier in the combined therapeutic and diagnostic approach to cancer treatment, IISER Kolkata said.

Their project, titled ReSET (Reprogramming the Suppressive Environment of Tumour Microenvironment), addresses one of the biggest barriers in cancer therapy. According to the statement, “Cancer often hides behind special immune cells called T regulatory cells (Tregs), which suppress the body’s natural defence system. This makes standard therapies like immunotherapy or chemotherapy less effective.”

Taking a bold and innovative approach, the IISER Kolkata team is engineering probiotics that can detect tumors and disrupt Tregs activity, reactivating the immune system against cancer. In simple terms, they are converting friendly microbes into living, targeted medicines that could one day work from inside the patient’s body to make cancer treatment safer and more effective.

Moving beyond the lab, the students have integrated human practices into their design by engaging with oncologists, surgeons, cancer survivors, and NGOs. They have also organized outreach programs in schools, cancer awareness campaigns, and collaborated with hair donors and patient support groups. These dialogues helped shape the therapy to be scientifically sound, ethically responsible, and socially relevant.

The team emphasizes that their work is not only a scientific prototype but also a proof of concept demonstrating that India’s youth can drive world-class research. “By targeting the Tregs pathway with engineered bacteria, we hope to bring forward a completely new class of cancer therapeutics, one that will revolutionize the way we treat cancer,” the team noted.

The group of 11 undergraduate students from IISER Kolkata will represent their institute and India at the International Genetically Engineered Machine (iGEM) Grand Jamboree 2025, the world’s largest synthetic biology competition, to be held in Paris in October this year.

*Note: Except for the headline, this article has not been edited by FPJ’s editorial team and is auto-generated from an agency feed.*
https://www.freepressjournal.in/education/iiser-kolkata-develops-friendly-bacteria-to-combat-cancer-from-within-patients-body